Prognostic Determinants in Prostate Cancer

Overview

Journal Cancer J

Specialty Oncology

Date 2011 Dec 14

PMID 22157287

Citations 28

Authors

Neil E Martin

Lorelei A Mucci

Massimo Loda

Ronald A DePinho

Affiliations

Soon will be listed here.

Abstract

Clinical outcomes in prostate cancer are heterogeneous, and given the high prevalence of the disease, there is a pressing need to identify clinically useful markers of prognosis. Many clinical, pathological, molecular, and genetic factors have been investigated in this capacity, although relatively few are routinely used. With a growing understanding of the molecular pathogenesis of prostate cancer, there is the potential that the next generation of makers will prove sufficiently robust to guide the optimal management of men with prostate cancer. Here, we review the various clinical and molecular prognostic determinants in prostate cancer.

Citing Articles

Autonomous Tumor Signature Extraction Applied to Spatially Registered Bi-Parametric MRI to Predict Prostate Tumor Aggressiveness: A Pilot Study.

Mayer R, Turkbey B, Simone 2nd C Cancers (Basel). 2024; 16(10).

PMID: 38791901 PMC: 11120057. DOI: 10.3390/cancers16101822.

From molecular mechanisms of prostate cancer to translational applications: based on multi-omics fusion analysis and intelligent medicine.

Ren S, Li J, Dorado J, Sierra A, Gonzalez-Diaz H, Duardo A Health Inf Sci Syst. 2023; 12(1):6.

PMID: 38125666 PMC: 10728428. DOI: 10.1007/s13755-023-00264-5.

Application of Spectral Algorithm Applied to Spatially Registered Bi-Parametric MRI to Predict Prostate Tumor Aggressiveness: A Pilot Study.

Mayer R, Turkbey B, Choyke P, Simone 2nd C Diagnostics (Basel). 2023; 13(12).

PMID: 37370903 PMC: 10297157. DOI: 10.3390/diagnostics13122008.

Glycyl-tRNA Synthetase (GARS) Expression Is Associated with Prostate Cancer Progression and Its Inhibition Decreases Migration, and Invasion In Vitro.

Kish E, Gamallat Y, Choudhry M, Ghosh S, Seyedi S, Bismar T Int J Mol Sci. 2023; 24(5).

PMID: 36901698 PMC: 10001614. DOI: 10.3390/ijms24054260.

Assessing and testing anomaly detection for finding prostate cancer in spatially registered multi-parametric MRI.

Mayer R, Turkbey B, Choyke P, Simone 2nd C Front Oncol. 2023; 12:1033323.

PMID: 36698418 PMC: 9869917. DOI: 10.3389/fonc.2022.1033323.

References

Kollermann J, Weikert S, Schostak M, Kempkensteffen C, Kleinschmidt K, Rau T . Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment. J Clin Oncol. 2008; 26(30):4928-33. DOI: 10.1200/JCO.2007.15.0441. View

Boorjian S, Karnes R, Rangel L, Bergstralh E, Blute M . Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy. J Urol. 2008; 179(4):1354-60. DOI: 10.1016/j.juro.2007.11.061. View

Nelson C, Dunn R, Wei J, Rubin M, Montie J, Sanda M . Contemporary preoperative parameters predict cancer-free survival after radical prostatectomy: a tool to facilitate treatment decisions. Urol Oncol. 2003; 21(3):213-8. DOI: 10.1016/s1078-1439(03)00017-6. View

Mackey T, Borkowski A, Amin P, Jacobs S, Kyprianou N . bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology. 1998; 52(6):1085-90. DOI: 10.1016/s0090-4295(98)00360-4. View

Kattan M, Wheeler T, Scardino P . Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999; 17(5):1499-507. DOI: 10.1200/JCO.1999.17.5.1499. View

Stephenson A, Kattan M, Eastham J, Bianco Jr F, Yossepowitch O, Vickers A . Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol. 2009; 27(26):4300-5. PMC: 3651598. DOI: 10.1200/JCO.2008.18.2501. View

de Bono J, Scher H, Montgomery R, Parker C, Miller M, Tissing H . Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14(19):6302-9. DOI: 10.1158/1078-0432.CCR-08-0872. View

Siegel R, Ward E, Brawley O, Jemal A . Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61(4):212-36. DOI: 10.3322/caac.20121. View

Taplin M, Bubley G, Shuster T, FRANTZ M, Spooner A, Ogata G . Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med. 1995; 332(21):1393-8. DOI: 10.1056/NEJM199505253322101. View

10.

Penney K, Sinnott J, Fall K, Pawitan Y, Hoshida Y, Kraft P . mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol. 2011; 29(17):2391-6. PMC: 3107753. DOI: 10.1200/JCO.2010.32.6421. View

11.

Bussemakers M, van Bokhoven A, Verhaegh G, Smit F, Karthaus H, Schalken J . DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999; 59(23):5975-9. View

12.

Korets R, Motamedinia P, Yeshchina O, Desai M, McKiernan J . Accuracy of the Kattan nomogram across prostate cancer risk-groups. BJU Int. 2010; 108(1):56-60. PMC: 6373767. DOI: 10.1111/j.1464-410X.2010.09838.x. View

13.

Landers K, Burger M, Tebay M, Purdie D, Scells B, Samaratunga H . Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int J Cancer. 2004; 114(6):950-6. DOI: 10.1002/ijc.20760. View

14.

Yang G, Ayala G, De Marzo A, Tian W, Frolov A, Wheeler T . Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res. 2002; 8(11):3419-26. View

15.

Eggener S, Scardino P, Walsh P, Han M, Partin A, Trock B . Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol. 2011; 185(3):869-75. PMC: 4058776. DOI: 10.1016/j.juro.2010.10.057. View

16.

Andriole G, Crawford E, Grubb 3rd R, Buys S, Chia D, Church T . Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360(13):1310-9. PMC: 2944770. DOI: 10.1056/NEJMoa0810696. View

17.

Richmond P, Karayiannakis A, Nagafuchi A, Kaisary A, Pignatelli M . Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival. Cancer Res. 1997; 57(15):3189-93. View

18.

Andren O, Fall K, Franzen L, Andersson S, Johansson J, Rubin M . How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. J Urol. 2006; 175(4):1337-40. DOI: 10.1016/S0022-5347(05)00734-2. View

19.

Fordyce C, Heaphy C, Joste N, Smith A, Hunt W, Griffith J . Association between cancer-free survival and telomere DNA content in prostate tumors. J Urol. 2005; 173(2):610-4. DOI: 10.1097/01.ju.0000143195.49685.ce. View

20.

Schlomm T, Kirstein P, Iwers L, Daniel B, Steuber T, Walz J . Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res. 2007; 13(22 Pt 1):6579-84. DOI: 10.1158/1078-0432.CCR-07-1257. View